Courtney Marabella

Senior Editor, OncLive®
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for OncLive®. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. Email: cmarabella@onclive.com

Articles

Addition of Dalpiciclib to Fulvestrant Improves PFS in HR+ Advanced Breast Cancer

February 14th 2022

The addition of dalpiciclib to fulvestrant significantly prolonged progression-free survival vs fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to data from an interim analysis of the phase 3 DAWNA-1 trial.

The Magnificence of the Possible: Toni K. Choueiri Gets Giants of Cancer Care Award in GU Cancer

February 14th 2022

It is a life-changing experience to see people take the hurt, suffering, pain, and loss of cancer and transform it into a superhuman force for good and for hope.

Nivolumab Misses Mark in Japanese Patients With Platinum-Resistant Ovarian Cancer

January 18th 2022

Nivolumab did not significantly improve overall survival compared with chemotherapy in Japanese patients with platinum-resistant ovarian cancer.

Navigating the Nuances of Molecular Testing in NSCLC

January 7th 2022

Charu Aggarwal, MD, MPH, shares how to navigate the nuances of molecular testing in non–small cell lung cancer, key developments made in the treatment of those whose tumors harbor actionable mutations, and the role of PD-L1 expression in informing clinical decisions.

Hepatectomy Plus Adjuvant mFOLFOX6 Improves DFS in Liver-Only Metastatic CRC

January 6th 2022

Adjuvant chemotherapy with modified fluoropyrimidine, leucovorin, and oxaliplatin improved disease-free survival among patients with liver-only metastases from colorectal cancer who were treated with hepatectomy.

Tucatinib Triplet Maintains OS Benefit in HER2+ Breast Cancer With Brain Metastases

January 6th 2022

The combination of tucatinib, trastuzumab, and capecitabine continued to produce an improvement in overall survival compared with trastuzumab/capecitabine alone in patients with HER2-positive metastatic breast cancer who had stable or active brain metastases.

Tiragolumab Plus Atezolizumab Demonstrates Improvement in PFS, OS, ORR in PD-L1+ NSCLC

January 4th 2022

The addition of tiragolumab to atezolizumab produced a clinically meaningful improvement in progression-free survival, overall survival, and objective response rate compared with atezolizumab alone in the first-line treatment of patients with PD-L1–positive non–small cell lung cancer.

CIRCULATE-US Study Will Utilize Signatera MRD Test to Inform Treatment Decisions in Resected CRC

December 21st 2021

The Signatera personalized minimal residual disease test will be leveraged in the phase 2/3 CIRCULATE-US trial to inform treatment strategies in patients with early-stage colorectal cancer.

Pembrolizumab/Lenvatinib Plus Belzutifan or Quavonlimab Under Investigation in Advanced Clear Cell RCC

December 20th 2021

A phase 3 clinical trial will compare the safety and efficacy of a co-formulation of pembrolizumab and quavonlimab plus lenvatinib, and that of pembrolizumab, belzutifan, and lenvatinib, vs pembrolizumab/lenvatinib alone in the frontline treatment of patients with advanced renal cell carcinoma.

Multidisciplinary Approach is Key to Managing Belantamab Mafodotin–Associated Keratopathy in Myeloma

December 11th 2021

Sagar Lonial, MD, FACP, discusses strategies for managing belantamab mafodotin–associated keratopathy in patients with multiple myeloma.

Liso-cel Improves HRQoL Over Standard of Care in Relapsed/Refractory LBCL

December 9th 2021

Second-line lisocabtagene maraleucel demonstrated a favorable improvement in most patient-reported outcome domains compared with standard of care in patients with relapsed or refractory large B-cell lymphoma, and health-related quality of life was found to either be improved or maintained following treatment with the CAR T-cell therapy.

Standard IHC Assays Show Poor Accuracy in Identifying Low HER2 Expression in Breast Cancer

December 8th 2021

Survey data collected from more than 1400 laboratories around the world have demonstrated poor agreement in the evaluation of patients with breast cancer who have a low HER2 immunohistochemistry score of 0 or 1+ using standard HER2 assays.

Pembrolizumab Plus Chemotherapy Represents New Standard of Care for Metastatic TNBC With PD-L1 CPS ≥10

December 7th 2021

Pembrolizumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival vs chemotherapy alone in patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer who have a PD-L1 combined positive score of 10 or higher.

FDA Grants Fast Track Designation to ST101 for Recurrent Glioblastoma

December 6th 2021

The FDA has granted a fast track designation to ST101, a peptide antagonist of C/EBPβ, for the treatment of patients with recurrent glioblastoma.

Cleveland Clinic Launches Trial Examining Preventive Vaccine for TNBC

December 2nd 2021

Cleveland Clinic has partnered with Anixa Biosciences, Inc. to open a phase 1 trial examining a vaccine aimed at preventing the development of triple-negative breast cancer.

Atezolizumab Provides Option for Patients With NSCLC at High Risk of Recurrence

December 2nd 2021

Nasser Khaled Altorki, MD, provides insight on the results of the IMpower010 trial as well as post hoc analyses from the trial and what they signal for the remainder of this patient population.

FDA Places Partial Clinical Hold on KO-539 Trial in Relapsed/Refractory AML

December 2nd 2021

The FDA has placed a partial clinical hold on the phase 1b KOMET-001 trial, which is examining KO-539 in patients with relapsed or refractory acute myeloid leukemia.

Niraparib Demonstrates PFS Benefit in Chinese Population With Advanced Ovarian Cancer

November 30th 2021

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.

Mirvetuximab Soravtansine Shows Promising Topline Results in FRα-High, Platinum-Resistant Ovarian Cancer

November 30th 2021

The antibody-drug conjugate mirvetuximab soravtansine has shown promising response rates and a favorable toxicity profile in patients with folate receptor alpha-high, platinum-resistant ovarian cancer who have received previous treatment with bevacizumab.

Multigene Panel Testing Identifies Actionable Germline Mutations in Newly Diagnosed Endometrial Cancer

November 26th 2021

Investigators identified potentially actionable germline variants in 10% of unselected women with newly diagnosed endometrial cancer, supporting the use of upfront multigene panel testing for all in the population.